Skip to content

APELLIS PHARMACEUTICALS, INC.

CIK 0001492422

← back to feed
Revenue (TTM)
$1.07B
+28.5% YoY Q1 Apr 2026
Net Income (TTM)
$100M
+111.3% YoY Q1 Apr 2026
EPS Diluted (TTM)
$0.75
+112.5% YoY Q1 Apr 2026
Gross Margin
—
Q1 Apr 2026
Operating Margin
12.4%
Q1 Apr 2026
Net Margin
9.3%
Q1 Apr 2026
Free Cash Flow (TTM)
−$425.63M
Q1 Apr 2026
Cash
$405.21M
Q1 Apr 2026
Total Debt
$94.78M
Q1 Apr 2026
Shares Outstanding
128.02M sh
Q1 Apr 2026

Revenue & Net Income

EPS (Diluted)

Margins

Cash Flow

Revenue Growth (YoY)

Balance Sheet

Cash vs Debt

Recent filings